



# ACCESS TO INSULIN TOOLKIT



## ACCISS TOOLKIT OVERVIEW

Molly Lepeska, Project Manger, ACCISS Study Health Action International



# ACCESS TO INSULIN TOOLKIT

- Estimation of need for insulin in type 1 and type 2

ABOUT

NEED FOR  
INSULIN



- Country need estimates
- Price data (where available)

- Transition guidelines
- Case studies of countries providing insulin for free
- Cost of care model
- Managing diabetes
- Alternative funding mechanisms for insulin

HEALTH  
SYSTEMS

PRICE OF  
INSULIN

INSULIN  
SELECTION

- Review on the value of insulin
- Guideline on different issues surrounding the use of insulin
- Biosimilar insulin FAQs
- Interchangeability

- Advocacy communications guide
- Insulin FAQs
- Infographics and more

COMMUNICATIONS

- Clearing house: govt. procurement, patient prices, reimbursement
- Estimation of cost of production of insulin
- Addressing mark-ups in the supply chain



# NEED FOR INSULIN

## ESTIMATE OF NEED

### **What?**

- First ever estimate of all people in need of insulin – for type 1 and type 2 diabetes.

### **Who?**

- This can be used by everyone; advocates, policymakers.
- Type 2 numbers went global in November. Type 1 estimates for all ages is set for June release

### **More info on the tool/how you can use this:**

These are estimates based on models. How do these numbers compare to existing data in your country?

# ACCESS TO INSULIN TOOLKIT



## What?


- Interactive map that includes estimates for diabetes and national price data (where available)

## Who?

- General public to help visualise the global need for insulin and how prices work.
- Connected to more in-depth price procurement database/ diabetes estimates

**More info on the tool/how you can use this:**

What other elements would improve the map?



# HEALTH SYSTEMS

Tools to help create system-wide change. These tools can be used in combination or independently.


TRANSITION  
GUIDELINES

CASE  
STUDIES

COST OF  
CARE MODEL

MANAGING  
DIABETES  
COMING SOON

ALTERNATIVE  
FUNDING



# HEALTH SYSTEMS

## TRANSITION GUIDELINES

### What?

- 10–step guide that highlights what is needed for LMICs to transition from an insulin-donation dependent programme to a sustainable national diabetes programme

### Who?

- Donors, national health policymakers and current diabetes programmes (underlines the importance of things such as monitoring quality of insulin donations, advice to improve reporting, etc)

### **More info on the tool/how you can use this:**

This tool is currently being piloted in Tanzania and we hope that this will refine the approach.



# HEALTH SYSTEMS

## CASE STUDIES

### What?

- Case studies provide an overview of challenges and opportunities that five LMICs faced when supplying free insulin as part of universal health care coverage. Background policies through current procurement processes discussed.

### Who?

- Health policymakers and national organisations dealing with health financing. These experiences will be useful when designing or improving national diabetes programmes.

**More info on the tool/how you can use this:**

A best practice summary coming soon. What elements are important for your work?





# HEALTH SYSTEMS

## ALTERNATIVE FUNDING

Available in:  
EN, RU, ES, FR

### **What?**

Discussion around 4 alternative funding strategies:

1. A tax on sugar-sweetened beverages earmarked for insulin
2. An international transaction tax to support insulin procurement
3. Trademark-based revenue generation approaches
4. Social impact bonds

### **Who?**

A background document for policymakers when considering alternative funding mechanisms for supplying insulin.

### **More info on the tool/how you can use this:**

This is only a practice guideline a not a “how to”. Might something more practical be helpful?





# HEALTH SYSTEMS

## MANAGING DIABETES

### What?

- This model presents a step by step approach to building a positive environment for type 1 diabetes management by focusing on meeting the key needs of individuals.

### Who?

- Policymakers and advocates looking to create or improve diabetes services in LMICs.

### More info on the tool/how you can use this:

Coming soon! This approach to type 1 diabetes care can be used as a tracer to other chronic conditions.



# HEALTH SYSTEMS

## COST OF CARE MODEL

User guide available in:  
EN, RU, ES, FR

### **What?**

This Excel Calculator estimates the direct annual medical cost of providing clinical care for people with diabetes at a national level.

### **Who?**

The tool is directed towards policymakers, health system financiers and other key stakeholders about the appropriate degree of financing necessary to address diabetes treatment

### **More info on the tool/how you can use this:**

This tool can be used in a dynamic way, e.g. how would costs be effected by a decrease in insulin prices? Complication rates? Types of insulin purchase? We encourage you to test and share your experiences, particularly using your own data.



# INSULIN SELECTION

Tools in this section aim to provide a better understanding of the options available when selecting an insulin type.

VALUE OF  
INSULIN

BIOSIMILAR  
FAQS

INTERCHAN-  
GEABILITY

GUIDELINES  
FOR USE



# INSULIN SELECTION

## VALUE OF INSULIN

Available in:  
EN, RU, ES, FR

### What?

- This guidance document is based on a review of published cost-effectiveness studies comparing analogues to human insulin, with detailed information on recent studies, reviews and meta-analyses.

### Who?

- Policymakers and reimbursement authorities to support decisions regarding the insulin purchase and reimbursement.

### More info on the tool/how you can use this:

This can be used to develop national guidelines for purchase, reimbursement and prescription of insulin.



# INSULIN SELECTION

## INTERCHAN- GEABILITY

### What?

- Information on the different regulatory approaches of the FDA and EMA towards interchangeability of biosimilars. Offers a better understanding of the clinical impact of switching between reference and biosimilar insulins, as seen from countries with experience in regulating biosimilars.

### Who?

- National regulators, national formulary committees and committees preparing clinical guidelines on insulin use.

### **More info on the tool/how you can use this:**

As a companion to the insulin guidelines for preparing clinical guidelines.  
To promote understanding of regulatory pathways between FDA and EMA.



# INSULIN SELECTION

## GUIDELINES FOR USE

Available in:  
EN, RU, ES, FR

### **What?**

This document reviews the evidence on four important clinical topics:

1. Clinical outcomes of human versus analogue insulin.
2. Clinical outcomes of pen delivery versus syringe and vial.
3. Use of insulin in type 2 diabetes.
4. Interchangeability of common insulins and biosimilars.

### **Who?**

- National and institutional formulary committees, committees preparing national clinical guidelines on the use of insulin.

**More info on the tool/how you can use this:**

Should be used to inform clinical guidelines. Lessons learned to be tracked



# PRICE OF INSULIN

This section includes reports and guidance on insulin manufacturing costs, actual government procurement prices, and regulating national supply chains, all aimed at improving insulin affordability.

COST OF  
PRODUCTION

PROCUREMENT  
PRICES

MARK-UPS  
COMING SOON



MORE ON  
PRICES





# PRICE OF INSULIN

## COST OF PRODUCTION

### What?

- This article, published in [BMJ Global Health](#), provides an estimate for the cost of production for human and analogue insulins, as well as estimates of what profitable prices should be with increased biosimilar competition.

### Who?

- National policymakers, high-level policymakers in health, financing and economics, insulin manufacturers, insulin advocates

### More info on the tool/how you can use this:

Compare estimate cost of production to your government procurement prices. Use for advocacy.



# PRICE OF INSULIN

PROCUREMENT  
PRICES

- **What?**  
A clearinghouse of actual prices paid by governments willing to share this information.
- **Who?**  
Government procurement officials and policymakers and others who are purchasing insulin.

**More info on the tool/how you can use this:**

Increase price transparency and push other countries to share their prices.  
Plan to expand to patient prices.



# PRICE OF INSULIN

## MARK-UPS

- **What?**  
Identifies the various mark-ups, taxes, tariffs, and other add-ons that add to the final price of insulin and presents potential interventions at country level to reduce their impact on insulin prices.
- **Who?**  
National policy makers, national price regulation authorities, high-level policy makers in health, financing and economics, and national diabetes programmes



# COMMUNICATIONS

COMMS TOOLKIT  
COMING SOON

FAQS

BARRIERS TO  
ACCESS

Please visit:

<http://accisstoolkit.haiweb.org/>

TOOLKIT

What else can we add?

Molly Lepeska, Project Manger, ACCISS Study, Health Action International  
molly@haiweb.org